[go: up one dir, main page]

AR086184A1 - Procedimiento de preparacion de un producto de plasma deplecionado de uno o varios factores trombogenicos - Google Patents

Procedimiento de preparacion de un producto de plasma deplecionado de uno o varios factores trombogenicos

Info

Publication number
AR086184A1
AR086184A1 ARP120101346A ARP120101346A AR086184A1 AR 086184 A1 AR086184 A1 AR 086184A1 AR P120101346 A ARP120101346 A AR P120101346A AR P120101346 A ARP120101346 A AR P120101346A AR 086184 A1 AR086184 A1 AR 086184A1
Authority
AR
Argentina
Prior art keywords
procedure
preparation
thrombogenic factors
plasma product
product
Prior art date
Application number
ARP120101346A
Other languages
English (en)
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45974358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of AR086184A1 publication Critical patent/AR086184A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Procedimiento de preparación de un producto de plasma deplecionado de uno o varios factores trombogénicos, que incluye la combinación de al menos dos etapas elegidas entre: una etapa de fraccionamiento con etanol; una etapa de filtración-adsorción; una etapa de precipitación con ácido caprílico; y una etapa de cromatografía con resina intercambiadora de iones.Reivindicación 12: Producto de plasma deplecionado de uno o varios factores trombogénicos, susceptible de obtenerse mediante el procedimiento de cualquiera de las reivindicaciones 1 a 11. Reivindicación 16: Producto farmacéutico que incluye el producto de plasma según cualquiera de las reivindicaciones 12 a 15 y al menos un vehículo farmacéuticamente aceptable.
ARP120101346A 2011-04-20 2012-04-19 Procedimiento de preparacion de un producto de plasma deplecionado de uno o varios factores trombogenicos AR086184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1153438A FR2974301B1 (fr) 2011-04-20 2011-04-20 Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes

Publications (1)

Publication Number Publication Date
AR086184A1 true AR086184A1 (es) 2013-11-27

Family

ID=45974358

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101346A AR086184A1 (es) 2011-04-20 2012-04-19 Procedimiento de preparacion de un producto de plasma deplecionado de uno o varios factores trombogenicos

Country Status (6)

Country Link
EP (1) EP2699248B1 (es)
AR (1) AR086184A1 (es)
ES (1) ES2624245T3 (es)
FR (1) FR2974301B1 (es)
TW (2) TWI584810B (es)
WO (1) WO2012143484A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2974301B1 (fr) * 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
CN103613662A (zh) * 2013-11-26 2014-03-05 中国医学科学院输血研究所 一种从人血浆中分离纯化人抗凝血酶-ⅲ的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE545232A (es) 1955-02-23
NL289602A (es) 1962-03-01
US4272521A (en) * 1979-07-16 1981-06-09 Cutter Laboratories, Inc. Purified immune serum globulin
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE59009020D1 (de) * 1990-03-22 1995-06-08 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates.
FR2676231A1 (fr) 1991-05-07 1992-11-13 Aetsrn Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6281336B1 (en) 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
RU2197500C2 (ru) 1998-06-09 2003-01-27 Статенс Серум Институт Способ получения иммуноглобулинов для внутривенного введения и другие иммуноглобулиновые продукты
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
FR2895263B1 (fr) * 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
EP2435474A2 (en) 2009-05-27 2012-04-04 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2974301B1 (fr) * 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
US20140044742A1 (en) 2011-04-20 2014-02-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for preparing a depleted plasma material consisting of one or more thrombogenic factors

Also Published As

Publication number Publication date
EP2699248A1 (fr) 2014-02-26
EP2699248B1 (fr) 2017-02-08
FR2974301B1 (fr) 2013-08-23
TWI526214B (zh) 2016-03-21
TW201306850A (zh) 2013-02-16
TW201507727A (zh) 2015-03-01
FR2974301A1 (fr) 2012-10-26
ES2624245T3 (es) 2017-07-13
WO2012143484A1 (fr) 2012-10-26
TWI584810B (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
AR125321A2 (es) Compuesto cristalino, método de preparación y composición que lo comprende
WO2016071293A3 (en) Pharmaceutical compound
MX2014001497A (es) Profarmacos de trepostinil enlazados a un portador.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
UY36275A (es) Compuestos aminopirimidinilo
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
WO2015040640A3 (en) An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
GT201300253A (es) Preparacion de gadobutrol de alta pureza
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2012125488A8 (en) C4-monomethyl triterpenoid derivatives and methods of use thereof
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
WO2012082718A3 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
ECSP11011065A (es) Composición farmacéutica de un potente inhibidor de hcv para su administración oral
NZ721952A (en) Delayed release compositions of linaclotide
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2012138713A3 (en) Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
PH12016500985A1 (en) Use of benzimidazole-proline derivatives
WO2013071174A3 (en) Styrene-siloxane triblock copolymers as membranes for selective transport of alcohols and other organic compounds in aqueous mixtures
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
AU2012283449A8 (en) Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2012096939A3 (en) Highly concentrated liquid acetaminophen solutions
UY33459A (es) Purificación de productos anfóteros, o de productos propensos a ser convertidos en productos anfóteros
AR086184A1 (es) Procedimiento de preparacion de un producto de plasma deplecionado de uno o varios factores trombogenicos
WO2012099899A3 (en) Topical dermatological compositions for the treatment of acne
MX2016009347A (es) Proceso para la reconstitucion de una forma solida de una composicion farmaceutica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure